Clinical trials: Transitional Cell Cancer of the Renal Pelvis and Ureter
Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
This randomized clinical trial studies the Family Caregiver Palliative Care Intervention in supporting caregivers of patients with stage II-IV gastrointestinal, gynecologic, urologic and lung cancers.
- Conditions
- Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT01846520
- Testing
- educational intervention, telephone-based intervention, quality-of-life assessment
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
R115777 in Treating Patients With Advanced Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have advanced bladder…
- Trial name
- NCT00006376
- Testing
- chemotherapy, tipifarnib
- Where
- 2 sites in United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
This is a prospective, open, multiple-center clinical study of renal preservation therapy in high-risk upper urinary tract urothelial carcinoma patients .
- Conditions
- Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC, PD-1antibody
- Trial name
- NCT05912816
- Testing
- RC48 Combined With Tislelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
This phase II trial compares therapeutic plasma exchange followed by enfortumab vedotin and pembrolizumab to standard of care next-line therapy for the treatment of patients with bladder or upper urinary tract cancers that have…
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma
- Trial name
- RECIPE-B1 (NCT07087860)
- Testing
- Best Practice, Biospecimen Collection, Central Venous Cannula Insertion
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Mayo Clinic
Urothelial Carcinoma of the Renal Pelvis and Ureter, Transitional Cell Cancer of the Renal Pelvis and Ureter
Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma
The goal of this prospective clinical trial is to investigate the safety and efficacy of ST-02 (mucoadhesive gemcitabine suspension for pyelocaliceal instillation) to treat Upper Tract Urothelial Carcinoma (UTUC) in participants…
- Trial name
- NCT06124976
- Testing
- ST-02
- Where
- 8 sites in Canada
- Volunteers
- 70 people
- Sponsor
- Peter Black
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT01118039
- Testing
- sunitinib malate, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 4 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Hospital del Mar
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT01089088
- Testing
- cisplatin, gemcitabine hydrochloride, sunitinib malate
- Where
- 16 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- Cardiff University
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Distal Urethral Cancer, Proximal Urethral Cancer
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
This phase II trial is studying the side effects and how well pazopanib works in treating patients with metastatic urothelial cancer.
- Conditions
- Distal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00471536
- Testing
- pazopanib hydrochloride
- Where
- 9 sites in United States, China and 1 more
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for urinary tract cancer.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00022191
- Testing
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 234 sites in United States, Australia and 14 more
- Volunteers
- 608 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT01090466
- Testing
- cisplatin, gemcitabine hydrochloride, temsirolimus
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Cardiff University
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
Phase II trial to study the effectiveness of combining trastuzumab with combination chemotherapy in treating patients who have locally recurrent or metastatic urinary tract cancer.
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Squamous Cell Carcinoma of the Bladder
- Trial name
- NCT00005831
- Testing
- trastuzumab, paclitaxel, carboplatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Renal Pelvis and Ureter Urothelial Carcinoma
Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
This phase II clinical trial tests how well pembrolizumab plus enfortumab vedotin prior to and after radical nephroureterectomy works in treating patients with high-risk upper tract urothelial cancer.
- Trial name
- NCT05775471
- Testing
- Biopsy, Biospecimen Collection, Enfortumab Vedotin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
This phase II trial is studying how well sorafenib works in treating patients with advanced or metastatic cancer of the urinary tract.
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00112671
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00005644
- Testing
- gemcitabine hydrochloride, paclitaxel
- Where
- 16 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have…
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00006026
- Testing
- rubitecan
- Where
- 11 sites in Belgium, France and 5 more
- Volunteers
- 21 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
RATIONALE: Drugs used in chemotherapy such as irinotecan use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00066612
- Testing
- irinotecan hydrochloride
- Volunteers
- 45 people
- Sponsor
- SWOG Cancer Research Network
Renal Pelvis and Ureter Urothelial Carcinoma
Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer
This phase Ib trial studies the side effects of infigratinib before surgery in treating patients with upper tract urothelial cancer.
- Trial name
- NCT04228042
- Testing
- Infigratinib, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter
Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
【Treatment of Urothelial Carcinoma】 Treatment for urothelial carcinoma includes surgery, chemotherapy (anticancer drugs), and radiation therapy.
- Conditions
- Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra, Urothelial Carcinoma Recurrent
- Trial name
- GRAPE (NCT06983210)
- Testing
- Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy
- Where
- Japan
- Volunteers
- 43 people
- Sponsor
- Nagoya University
Urinary Tract Cancer, Urothelial Carcinoma
CLE Characteristics of Upper Urinary Tract Urothelial Carcinoma
Rationale: Initial evaluation usually consists of cross sectional imaging of the urinary tract. When a suspect lesion is seen, an ureterorenoscopy is planned to visualize the lesion and to collect tissue for histopathology.
- Conditions
- Urinary Tract Cancer, Urothelial Carcinoma, Ureter Cancer
- Trial name
- NCT03013920
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)